Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation and Dose-Expansion Study of iMagic Injection in Participants With Relapsed/Refractory Hematologic Malignancies

NCT07802756 is registered in ClinicalTrials.gov with Suzhou Immunofoco Biotechnology Co., Ltd as lead sponsor.

NCT NCT07802756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07802756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation and Dose-Expansion Study of iMagic Injection in Participants With Relapsed/Refractory Hematologic Malignancies
Lead sponsor
Suzhou Immunofoco Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 10, 2026
Completion date
September 10, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory hematologic malignancies